Alpha interferon and ribavirin combination therapy of chronic hepatitis D.
The success of alpha interferon (IFN-alpha) monotherapy for the treatment of chronic hepatitis D is very limited. In this study, the efficacy of IFN-alpha and ribavirin combination therapy for chronic hepatitis D was investigated. Nineteen patients (15 males; mean age +/- standard deviation, 36.8 +/- 12.8 years) with chronic hepatitis D who were treated with IFN-alpha2b (10 million U, three times/week, subcutaneously) and ribavirin (1,000 to 1,200 mg/day, orally) for 24 months were studied. All patients had compensated liver disease (15 were precirrhotic), elevated transaminase levels, and hepatitis D virus RNA positivity at baseline. Genotypic analyses revealed hepatitis D virus genotype I and hepatitis B virus genotype D. All patients completed the 24 months of treatment and at least 6 months (7 to 19 months) of a follow-up period. Biochemical responses were observed in eight patients (42.1%) at the end of treatment and in seven patients (36.8%) at the end of follow-up. Eight patients (42.1%) at the end of treatment and four patients (21%) at the end of follow-up had virological responses. In conclusion, combination treatment of IFN-alpha and ribavirin for chronic hepatitis D is not able to induce virological responses at a sufficient rate, despite its partial effectiveness in improving biochemical responses, and is not superior to IFN-alpha monotherapy.
Kaymakoglu
Sabahattin
S
Department of Gastroenterohepatology, Istanbul Medical Faculty, Istanbul University, Capa, 34390, Istanbul, Turkey. kaymakoglus@hotmail.com
Karaca
Cetin
C
Demir
Kadir
K
Poturoglu
Sule
S
Danalioglu
Ahmet
A
Badur
Selim
S
Bozaci
Murvet
M
Besisik
Fatih
F
Cakaloglu
Yilmaz
Y
Okten
Atilla
A
D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage*; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D005260:Female; D003699:Hepatitis D / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage*
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin
Gastroenterology. 1999 Nov;117(5):1229-33
10535887
Gastroenterology. 1999 Jul;117(1):161-6
10381923
J Gen Virol. 2001 Nov;82(Pt 11):2709-18
11602783
J Hepatol. 2002 Aug;37(2):266-71
12127433
Gut. 1977 Dec;18(12):997-1003
75123
Hepatology. 1981 Sep-Oct;1(5):431-5
7308988
Ann Intern Med. 1983 Apr;98(4):437-41
6340574
Semin Liver Dis. 1984 Nov;4(4):340-6
6395342
J Clin Microbiol. 1990 Mar;28(3):495-503
1691208
Prog Clin Biol Res. 1991;364:411-20
2020718
Hepatology. 1991 Jun;13(6):1052-6
2050321
J Hepatol. 1991;13 Suppl 1:S21-6
1835731
N Engl J Med. 1994 Jan 13;330(2):88-94
8259188
Liver. 1994 Jun;14(3):154-7
8078394
Liver. 1995 Feb;15(1):45-52
7776857
J Virol. 1997 Mar;71(3):2241-51
9032359
Hepatology. 1997 Mar;25(3):728-34
9049226
J Gen Virol. 1998 Oct;79 ( Pt 10):2381-91
9780043
J Viral Hepat. 2000 Nov;7(6):428-34
11115054